Fulgent Genetics (MEX:FLGT) Loans Receivable : MXN0 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics Loans Receivable?

Fulgent Genetics's Loans Receivable for the quarter that ended in Mar. 2024 was MXN0 Mil.

Fulgent Genetics Loans Receivable Historical Data

The historical data trend for Fulgent Genetics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Loans Receivable Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Loans Receivable

Get a 7-Day Free Trial

Fulgent Genetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Fulgent Genetics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Fulgent Genetics Loans Receivable Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics (MEX:FLGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.